Trial Profile
Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Perifosine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Jul 2017 Planned number of patients changed from 36 to 38.
- 31 Jul 2017 Status changed from active, no longer recruiting to completed.
- 19 Sep 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.